Quvara Medical Emerges as Latest CDMO in Growing Trend of Contract Manufacturing Expansions

In a year marked by significant growth in the contract development and manufacturing organization (CDMO) sector, Quvara Medical has made its debut as the newest player in the field. The launch comes as part of a strategic acquisition by the Buckland Group, which purchased a former Becton Dickinson manufacturing facility in Swindon, England, for an undisclosed sum.

Acquisition and Facility Details

The newly acquired Swindon site, operational for two decades, specializes in the production of prefilled syringes. This high-precision, high-volume manufacturing capability positions Quvara Medical to cater to both the medical device and pharmaceutical industries. Paul Bragg, Buckland's managing director, emphasized the strategic nature of this acquisition, stating, "This acquisition is part of our strategy to build specialised, sector-leading businesses under the Quvara Group banner. Medical manufacturing is the first—but not the last area where we're applying this model."

While financial terms were not disclosed, Quvara Medical confirmed that the facility remains fully operational with complete workforce retention, ensuring continuity of expertise and production capabilities.

Industry Context and Competition

Quvara Medical's launch is part of a broader trend in the pharmaceutical industry, with at least five CDMOs having debuted in 2025 alone. This group includes Rezon Bio, Codis, Meribel, and Artis BioSolutions, each carving out its niche in the competitive CDMO landscape.

Neil Sibley, chief executive of Quvara Medical, highlighted the company's value proposition: "We offer clients the speed, agility, and compliance they demand, built on decades of manufacturing excellence." This focus on agility and compliance underscores the increasing importance of flexible, high-quality manufacturing capabilities in the pharmaceutical sector.

Recent CDMO Landscape Developments

The CDMO sector has seen a flurry of activity in recent months. Notably, Codis launched following a deal that combined U.S.-based Particle Dynamics with a U.K. spray drying plant previously operated by EuroAPI. In September, Rezon Bio entered the market with a focus on biologics, backed by two manufacturing sites in Poland. Earlier in the year, Meribel was established after acquiring production sites from Recipharm and purchasing France's Synerlab. Additionally, Artis BioSolutions launched as a specialized CDMO focusing on cell and gene therapies.

These developments reflect a growing trend of strategic acquisitions and launches in the CDMO space, as pharmaceutical companies increasingly outsource manufacturing to specialized partners. The emergence of new players like Quvara Medical indicates a robust and expanding market for contract manufacturing services in the life sciences sector.